evidencegaps
Primary study · included by 1 review

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE).

Duan 2022 · Duan Hongtao, Shao Changjian, Pan Minghong, et al. · Frontiers in immunology · 2022

Included by

The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck, Cervical, Lung, Cutaneous, and Oral Squamous Cell Carcinomas.
Non-Cochrane · intervention · 2026 · cited as Duan 2022 · Supplementary Table S1; reference list

The review does not say which of its outcomes this study informs.

1 including review in total.